Everyone Wins With This Biotech Buyout
From the smallest biotech to the biggest pharmaceutical stock, The Motley Fool's Market Check-Up covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.
In this segment, health-care analyst David Williamson takes a look at the upcoming acquisition by Salix Pharmaceuticals of Santarus for about $2.6 billion. Salix is currently a maker of drugs for gastrointestinal diseases, and the immediately accretive deal will give Salix access to treatments for both diabetes and heartburn. Shares of both companies were up significantly on the news. David tells investors why shareholders should be pleased with this deal on both ends and what he thinks of the stock going forward.
More Foolish insight
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
Follow David on Twitter @MotleyDavid.
The article Everyone Wins With This Biotech Buyout originally appeared on Fool.com.David Williamson owns shares of Merck. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.